Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptinyx Inc (APTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8164
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptinyx Inc. (Aptinyx), formerly Enarex Inc, is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of neurological disorders. The company’s proprietary chemistry platform helps develop a pipeline of small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors and improves synaptic plasticity. Many NMDA receptor modulators are under clinical development as differentiated therapies for depression, and they possess efficacy and safety with the potential to treat various neurologic disorders. The company’s pipeline products include NYX-2925, which is under clinical development as a therapy for neuropathic pain; NYX-783, for post-traumatic stress disorder (PTSD); and NYX-458, for the treatment of cognitive impairment associated with Parkinson’s disease. Aptinyx is headquartered in Evanston, Illinois, the US.

Aptinyx Inc (APTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Partnerships 16
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Equity Offering 18
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc – Key Competitors 21
Aptinyx Inc – Key Employees 22
Aptinyx Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 14, 2018: Aptinyx announces second quarter 2018 financial results 24
Corporate Communications 26
May 17, 2018: Aptinyx Appoints Robert Hombach to Board of Directors 26
May 03, 2018: Aptinyx Promotes David Houck to Chief Development Officer 27
Feb 13, 2018: Aptinyx Names Ashish Khanna As Chief Financial Officer and Chief Business Officer 28
Dec 07, 2017: Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as Chief Commercial Officer 29
Clinical Trials 30
Mar 15, 2018: Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Aptinyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc, Key Competitors 21
Aptinyx Inc, Key Employees 22
Aptinyx Inc, Other Locations 23

List of Figures
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biohit Oyj (BIOBV):企業の財務・戦略的SWOT分析
    Summary Biohit Oyj (Biohit) is a biotechnology company that offers research and early diagnosis processing products. The company’s products comprise acetaldehyde binding products, diagnostic tests, dysbiosis test, microplate readers and washers, monoclonal antibodies, and pipettes. It targets therap …
  • City Developments Ltd:戦略・SWOT・企業財務分析
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • VTT Technical Research Centre of Finland-製薬・医療分野:企業M&A・提携分析
    Summary VTT Technical Research Centre of Finland (VTT) is a research and technology center that offers development services. The center provides research services on bioeconomy and circular economy, health and wellbeing, digital society, low carbon energy, smart industry, sustainable and smart city, …
  • Lloyd’s Register Group Ltd:企業の戦略的SWOT分析
    Lloyd's Register Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Debiotech SA-医療機器分野:企業M&A・提携分析
    Summary Debiotech SA (Debiotech) is a medical device company that develops therapeutic devices and diagnostic products. The company’s products include patch-pump, injection, multi-fluidic cassette type system, infusion pump and microsystems. It develops products in the areas of implantable and exter …
  • Oge Energy Corp
    Oge Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Oge Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Savara Inc (SVRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include M …
  • Teco Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary TECO Energy Inc (TECO), a subsidiary of Emera Inc., is an energy holding company for regulated electricity and gas utilities and other businesses. It generates, transmits, distributes, purchases and sells electricity; and purchases, distributes and sells natural gas through its subsidiaries. …
  • Owensboro Municipal Utilities:企業の戦略的SWOT分析
    Owensboro Municipal Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Golden Valley Mines Ltd. (GZZ):企業の財務・戦略的SWOT分析
    Golden Valley Mines Ltd. (GZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • NeuStar, Inc.:企業の戦略的SWOT分析
    NeuStar, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • University of California Berkeley:製薬・医療:M&Aディール及び事業提携情報
    Summary University of California Berkeley (UC Berkeley), a subsidiary of University of California is an educational university that offers educational programs and research services. The university’s academic programs comprise law and economics program, legal studies; lesbian, gay, bisexual, and tra …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Biofortuna Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Biofortuna Ltd (Biofortuna) is a provider of contract services and molecular diagnostic products. The company distributes CE-marked and freeze-dried PCR diagnostic kits. It has freeze dried molecular diagnostic products targeted at the transplantation, disease identification and pharmacogene …
  • SimCorp AS (SIM):企業の財務・戦略的SWOT分析
    SimCorp AS (SIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報
    Summary La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company’s major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressu …
  • Petrochemical Corporation of Singapore (Private) Ltd:企業の戦略的SWOT分析
    Petrochemical Corporation of Singapore (Private) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key comp …
  • Minerals Technologies Inc (MTX):企業の財務・戦略的SWOT分析
    Minerals Technologies Inc (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Nestle Australia Ltd:企業の戦略・SWOT・財務分析
    Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Liquor Control Board of Ontario:企業の戦略的SWOT分析
    Liquor Control Board of Ontario - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆